This study was a double-blind randomized controlled clinical trial. From all obese patients referred to the endocrinology clinic of Afzalipour hospital and office for treatment, 66 non diabetic subjects were recruited to this study. Inclusion criteria were age equal or more than 18 years, willingness to participate in the study, BMI (weight[kg]/ height[m]2 ) between 25-35, no evidence of cardiovascular disease, diabetes, gastrointestinal disease (IBD, intestinal ulcers, bowel obstruction), liver disease and renal disease, no history of medication for lowering weight, women should not be pregnant or milking. The exclusion criteria were no desire to continue the treatment, development of renal, gastrointestinal and liver disease during treatment and beginning to utilize antihypertensive drugs such as β blocker and thiazides. At the beginning of study, the baseline characteristics of all selected subjects including height, weight, total cholesterol, and triglyceride (TG) and fasting blood glucose (FBS) were recorded. Patients were randomly assigned to receive acarbose or placebo. Randomization was performed centrally by a computer program with minimization for height, weight and BMI according to the study center. Treatment group was given acarbose pills (100mg) and other group took lactose contained placebo (100mg). Patients were given study medication1.5 tablets daily for the first two weeks and 3 tablets per day afterwards. Subjects were evaluated every month for adverse effects, weight loss and BMI for five months. At the baseline and once every three months blood samples for FBS, TG and Cholesterol were taken from patients